WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR March 2023 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • WJAHR: MARCH ISSUE PUBLISHED

    March 2024 Issue has been successfully launched on 1 March 2024.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

THE ADMINISTRATION OF N-ACETYLCYSTEINE AS PREVENTION OF NEPHROPATHY IN HIGH RISK PATIENTS UNDERGOING CORONARY ANGIOGRAPHY IN TERTIARY CARE HOSPITAL, KARACHI, PAKISTAN

Dr. Syed Meerab Javed, Dr. Afifa Saulat and *Dr. Anwar Nabeel Jafri

ABSTRACT

Introduction: Contrast induced nephropathy is reported to be the third most common cause of in hospital acute kidney injury. There are enormous impacts of the development of this complication in terms of hospital stay, morbidity, mortality and long term dialysis dependence. Since there are no appropriate treatments to this complication much of the focus has been on prevention. N-acetylcysteine is one of the most common drugs used in this perspective; however, there are a number of studies with conflicting results regarding the efficacy of this compound. Hence the need to evaluate the significance of this compound in prevention of contrast induced nephropathy in our population. Objective:To determine the frequency of contrast induced nephropathy in patients undergoing coronary angiography and intervention receiving N-acetylcystein as a prophylaxis at Aga Khan University Hospital. Study design: Cross sectional study. Settings: Department of Medicine, Aga Khan University Hospital. Materisls and Methods: Patients admitted in coronary care unit, Aga Khan university Hospital, receiving N-acetylcysteine as a prophylaxis for contrast induced nephropathy before coronary angiography and intervention were included in this study provided they meet the inclusion criteria. Serum creatinine were noted at the baseline and then at 48 hours post contrast exposure. An increase of 0.5 mg/dl above the baseline creatinine was labeled as contrast induced nephropathy. Comorbid conditions including diabetes and chronic kidney disease were noted, so were the age of the patient. Results: The frequency of contrast induced nephropathy in patients receiving N-acetylcysteine as a prophylaxis for coronary angiography and intervention was found to be 19.6%. The frequency was observed to increase with increase in age of the patients, mean serum creatinine of all patients on presentation was 1.557 (+/- 0.5539) mg/dl. All of these patients received N-acetylcysteine as a prophylaxis for contrast induced nephropathy and the mean serum creatinine 48 hours post exposure to contrast was found to be 1.632 (1.2001) mg/dl. Conclusion: Prophylactic administration of N-acetylcysteine for the prevention of contrast induced nephropathy fail to show a benefit in terms of prevention of contrast induced nephropathy, since, the frequency observed in this study was significantly higher to the incidence of contrast induced nephropathy reported in the earlier studies.

[Full Text Article] [Download Certificate]